Detalles de la búsqueda
1.
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Nat Immunol
; 23(9): 1379-1392, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36002648
2.
Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.
J Cell Physiol
; 232(8): 2246-2252, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987320
3.
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
BMC Cancer
; 17(1): 101, 2017 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28166748
4.
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Mol Cancer
; 20(1): 151, 2021 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34839818
5.
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
Oncologist
; 19(11): 1118-26, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25323485
6.
Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.
Int J Cancer
; 132(5): 1022-31, 2013 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22847294
7.
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Int J Cancer
; 133(5): 1259-65, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23404247
8.
Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report.
Front Oncol
; 12: 1050452, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36713585
9.
Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available.
J Clin Pathol
; 75(12): 844-850, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34400544
10.
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting.
Cancers (Basel)
; 14(12)2022 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35740637
11.
Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.
J Mol Diagn
; 24(9): 1021-1030, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35718095
12.
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study.
Cancers (Basel)
; 14(19)2022 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36230758
13.
High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis.
J Transl Med
; 9: 184, 2011 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-22032294
14.
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
Clin Breast Cancer
; 20(6): e761-e770, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32580907
15.
Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
J Exp Clin Cancer Res
; 39(1): 103, 2020 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32498717
16.
Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages.
J Immunother Cancer
; 8(1)2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32269145
17.
microRNA-378a-5p iS a novel positive regulator of melanoma progression.
Oncogenesis
; 9(2): 22, 2020 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32060259
18.
Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism.
Cancer Res
; 80(19): 4087-4102, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32718996
19.
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting.
Ther Adv Med Oncol
; 11: 1758835919853192, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31452691
20.
Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
J Exp Clin Cancer Res
; 37(1): 95, 2018 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29716630